Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
We are a program built around our people—residents and faculty alike—who are deeply committed to Tinsley Harrison’s legacy, which we proudly call Excellence Without Ego.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback